Published in Cancer Discovery, early trials show that sevabertinib can shrink tumours in patients with HER2 exon 20, a mutated lung cancer found in roughly 2-3 per cent of cases.
Advice comes at a time when India accounts for a 5th of global generic drug supply & 40% of generics used in US. However, this strength in finished formulations relies on imported ingredients.
It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.
COMMENTS